Oral atenolol (25 mg twice daily and 50 mg and 100 mg once daily) and placebo were tested
as additional therapy in a double-masked, randomised, cross-over study. Twenty-four …

In a controlled double-blind cross-over trial in 10 patients comprising six with open-angle
glaucoma, three with closed-angle glaucoma, and one with ocular hypertension, a single …

The effect of long-term application of 4% atenolol eye drops has been studied in patients
with either glaucoma or ocular hypertension. In some patients who show a good initial …

Abstract Oral atenolol (25, 50 and 100 mg) and placebo administered once daily were tested
in a double-masked, randomized cross-over study. Ten patients (18 eyes) who had …

Guttae atenolol 4%(Tenormin), a pure beta1-blocking (ie, cardioselective) drug, produced a
median overall fall of 5-6 mmHg (range 3-2 to 13-2 mmHg) in the first tonometrised eyes of 7 …

In a double-masked, 3-month clinical study the ocular hypotensive effects of diacetyl nadolol
(DAN), timolol, and nadolol were compared. When applied topically to the eyes of …

The ocular hypotensive effect of single oral doses of (a) atenolol (50 mg),(b) acetazolamide
(500 mg),(c) atenolol (50 mg) and acetazolamide (500 mg) in combination, and (d) vehicle …

Forty six normal volunteers were randomly assigned in double-blind fashion to once daily
orally administered nadolol 10, 20, 40, or 80 mg for five days. Significant and dose related …

Atenolol (Tenormin or ICI 66082) is a new beta-adrenergic blocking drug, unique in being
cardio-selective and in having no intrinsic sympathomimetic or membrane activity. In a …

Placebo and topical atenolol (Tenormin), a selective beta1-adrenergic blocking substance
with no intrinsic sympathomimetic or membrane-stabilising properties, were tested in 16 …